EP0647133A4 - Compositions and methods for enhanced drug delivery. - Google Patents
Compositions and methods for enhanced drug delivery.Info
- Publication number
- EP0647133A4 EP0647133A4 EP93915319A EP93915319A EP0647133A4 EP 0647133 A4 EP0647133 A4 EP 0647133A4 EP 93915319 A EP93915319 A EP 93915319A EP 93915319 A EP93915319 A EP 93915319A EP 0647133 A4 EP0647133 A4 EP 0647133A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- drug delivery
- enhanced drug
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89821992A | 1992-06-12 | 1992-06-12 | |
US898219 | 1992-06-12 | ||
US946393A | 1993-01-27 | 1993-01-27 | |
US9463 | 1993-01-27 | ||
PCT/US1993/005631 WO1993025197A1 (en) | 1992-06-12 | 1993-06-11 | Compositions and methods for enhanced drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0647133A1 EP0647133A1 (en) | 1995-04-12 |
EP0647133A4 true EP0647133A4 (en) | 1997-10-29 |
Family
ID=26679515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93915319A Withdrawn EP0647133A4 (en) | 1992-06-12 | 1993-06-11 | Compositions and methods for enhanced drug delivery. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0647133A4 (en) |
AU (1) | AU4534593A (en) |
WO (1) | WO1993025197A1 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
DK0688333T3 (en) * | 1993-03-10 | 1999-02-08 | Magainin Pharma | Steroid derivatives, pharmaceutical compositions containing them and their use as antibiotics or disinfectants |
US5505715A (en) * | 1994-02-25 | 1996-04-09 | Bristol-Myers Squibb Company | Iontophoretic transdermal delivery of deoxyspergualin compounds |
US6468981B1 (en) | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
US5840740A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
FR2727117A1 (en) * | 1994-11-18 | 1996-05-24 | Geffard Michel | USE OF POLYLYSIN CONJUGATES FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DEGENERATIVE DISORDERS OF AUTOIMMUN CHARACTER |
ATE241346T1 (en) † | 1995-03-02 | 2003-06-15 | Scherer Technologies Inc R P | MEDICINAL PRODUCTS CONTAINING MONOAMINOOXIDASE-B INHIBITORS |
US8071737B2 (en) | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US5747453A (en) * | 1995-06-06 | 1998-05-05 | Alza Corporation | Method for increasing the electrotransport flux of polypeptides |
IT1285405B1 (en) * | 1995-06-06 | 1998-06-03 | Alza Corp | MODIFICATION OF POLYPEPTIDE DRUGS TO INCREASE FLOW BY ELECTROTRANSPORT. |
US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5763430A (en) * | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US5840936A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
US5874597A (en) * | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5795885A (en) * | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
US5994336A (en) * | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
IT1283955B1 (en) * | 1996-03-20 | 1998-05-07 | Sigma Tau Ind Farmaceuti | BIS ALCANOIL ESTERS OF CARNITINE WITH ANTIBACTERIAL, ANTIMICOTIC AND ANTIPROTZOARY ACTIVITY. |
DK0910382T3 (en) * | 1996-04-26 | 2003-10-06 | Genaera Corp | Squalamine in combination with other anticancer agents for the treatment of tumors |
US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
US6333189B1 (en) | 1996-06-06 | 2001-12-25 | Alza Corporation | Method of making an electrotransport device |
US6262283B1 (en) | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
IT1299266B1 (en) * | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | REVERSIBLE CARNITINE PALMITOIL INHIBITORS TRANSFERRED |
WO2001079255A1 (en) | 2000-04-12 | 2001-10-25 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
KR100926921B1 (en) | 2001-06-11 | 2009-11-17 | 제노포트 인코포레이티드 | Prodrugs of BAAA analogs, compositions and uses thereof |
GB0116047D0 (en) * | 2001-06-29 | 2001-08-22 | Implyx Ltd | Peptide motif for therapy |
DE10303669A1 (en) * | 2003-01-28 | 2004-07-29 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | New quaternary ammonioalkyl carbonate esters useful for treating bacterial and fungal infections and potentially useful for regulating cholesterol biosynthesis |
WO2006050514A1 (en) | 2004-11-04 | 2006-05-11 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
JP5227593B2 (en) * | 2005-02-04 | 2013-07-03 | アメリカ合衆国 | Nandrolone 17β-carbonate |
US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
WO2008013860A2 (en) * | 2006-07-28 | 2008-01-31 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
CN101522692A (en) * | 2006-10-11 | 2009-09-02 | 于崇曦 | Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate |
EP3176169A1 (en) * | 2007-01-31 | 2017-06-07 | Chongxi Yu | Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates |
EP2111409B1 (en) * | 2007-02-13 | 2012-06-27 | Council of Scientific & Industrial Research | Novel cationic 17 alpha- substituted-estradiol derivatives useful as anti-cancer agent |
PL2170826T3 (en) | 2007-06-04 | 2022-09-05 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
EP2219587A4 (en) * | 2007-11-14 | 2012-11-21 | Univ California | Sterol-modified amphiphilic lipids |
CN108191846B (en) | 2008-12-04 | 2021-08-20 | 于崇曦 | High penetration composition and application thereof |
US8686009B2 (en) | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
PT2445502T (en) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
ES2857626T3 (en) | 2010-01-15 | 2021-09-29 | Suzhou Neupharma Co Ltd | Certain chemical entities, compositions, and methods |
WO2011163594A2 (en) | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
WO2012027957A1 (en) | 2010-08-28 | 2012-03-08 | Suzhou Neupharma Co., Ltd. | Bufalin derivatives, pharmaceutical compositions and use thereof |
WO2012103810A1 (en) | 2011-02-02 | 2012-08-09 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
PT3156056T (en) | 2011-03-18 | 2024-03-04 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising sorbitan esters |
JP2014514300A (en) * | 2011-04-08 | 2014-06-19 | スファエラ ファーマ ピーティーイー リミテッド | Substituted methylformyl reagents and methods for their use to modify the physicochemical and / or pharmacokinetic properties of compounds |
AU2012351747B2 (en) | 2011-12-15 | 2016-05-12 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
WO2013142198A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
ES2950418T3 (en) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
EP2852285B1 (en) | 2012-04-29 | 2018-08-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer |
CA2885196C (en) | 2012-09-19 | 2021-06-22 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
CN103896791B (en) * | 2012-12-25 | 2016-12-28 | 广东隆赋药业股份有限公司 | The preparation method of acetyl levocarnitine hydrochlorate |
GB201308363D0 (en) | 2013-05-09 | 2013-06-19 | Bagshawe Kenneth D | Tumour therapy |
BR112016021535A8 (en) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit comprising aripiprazole formulations having increased injection rates useful for the treatment of a central nervous system disorder and use |
CN104151452B (en) * | 2014-07-16 | 2017-02-01 | 西北大学 | Poly(N-(2-hydroxypropyl)methacrylamide)-lonidamine macromolecular prodrug and preparation method thereof |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN115851076B (en) * | 2022-12-21 | 2023-10-31 | 湖北航天化学技术研究所 | Graphene zinc-containing antirust paint and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023206A1 (en) * | 1979-11-02 | 1982-01-14 | Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover | Antiinflammatory indomethacin di:alkylamino-ethyl ester derivs. - prepd. by heating indomethacin with an O-di:alkyl:aminoethyl-N,N'-di:isopropyl isourea in benzene |
US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
EP0279887A2 (en) * | 1987-01-15 | 1988-08-31 | Alfred Stracher | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder |
EP0289262A2 (en) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs |
WO1991009831A1 (en) * | 1989-12-26 | 1991-07-11 | Nova Pharmaceutical Corporation | Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5085749A (en) * | 1989-03-14 | 1992-02-04 | Massachusetts Institute Of Technology | Dynamically controlled membrane |
-
1993
- 1993-06-11 AU AU45345/93A patent/AU4534593A/en not_active Abandoned
- 1993-06-11 EP EP93915319A patent/EP0647133A4/en not_active Withdrawn
- 1993-06-11 WO PCT/US1993/005631 patent/WO1993025197A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023206A1 (en) * | 1979-11-02 | 1982-01-14 | Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover | Antiinflammatory indomethacin di:alkylamino-ethyl ester derivs. - prepd. by heating indomethacin with an O-di:alkyl:aminoethyl-N,N'-di:isopropyl isourea in benzene |
US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
EP0279887A2 (en) * | 1987-01-15 | 1988-08-31 | Alfred Stracher | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder |
EP0289262A2 (en) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs |
WO1991009831A1 (en) * | 1989-12-26 | 1991-07-11 | Nova Pharmaceutical Corporation | Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use |
Non-Patent Citations (1)
Title |
---|
See also references of WO9325197A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0647133A1 (en) | 1995-04-12 |
WO1993025197A1 (en) | 1993-12-23 |
AU4534593A (en) | 1994-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0647133A4 (en) | Compositions and methods for enhanced drug delivery. | |
ZA942804B (en) | Oral drug delivery compositions and methods | |
EP0658111A4 (en) | Methods for enhancing drug delivery with modified saponins. | |
IL109661A0 (en) | Drug delivery device | |
EP0662851A4 (en) | Drug delivery system. | |
GB2271059B (en) | Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives. | |
IL110588A (en) | Bioadhesive emulsion preparations for enhanced drug delivery | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
EP0491812A4 (en) | Drug delivery compositions | |
EP0676963A4 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses. | |
EP0683668A4 (en) | Compositions and methods for transdermal drug delivery. | |
GB2272375B (en) | Pharmaceutical composition | |
AU1432292A (en) | Drug delivery composition and method of using the same | |
GB9325330D0 (en) | Fluorocyclodextrin drug delivery system | |
EP0600754A3 (en) | Constant pharmaceutical infuser. | |
GB9404293D0 (en) | Drug delivery system | |
IL107122A0 (en) | 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions | |
EP0636363A3 (en) | Drug delivery system. | |
GB2292887B (en) | Drug delivery system | |
ZA935931B (en) | Pharmaceutical composition | |
GB9223363D0 (en) | Drug etc.delivery | |
ZA931775B (en) | Drug delivery devices. | |
GB9324682D0 (en) | Drug delivery system | |
GB9307904D0 (en) | Drug delivery system | |
GB9303117D0 (en) | Drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950112 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR GB IT LI NL |
|
RHK1 | Main classification (correction) |
Ipc: A61K 47/48 |
|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19980120 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19980603 |